|
Q1 FY2027
As of May 31, 2026
|
Q4 FY2026
As of Feb 28, 2026
|
Q3 FY2026
As of Nov 30, 2025
|
Q2 FY2026
As of Aug 31, 2025
|
Q1 FY2026
As of May 31, 2025
|
Q4 FY2025
As of Feb 28, 2025
|
Q3 FY2025
As of Nov 30, 2024
|
Q2 FY2025
As of Aug 31, 2024
|
Q1 FY2025
As of May 31, 2024
|
Q4 FY2024
As of Feb 29, 2024
|
Q3 FY2024
As of Nov 30, 2023
|
Q2 FY2024
As of Aug 31, 2023
|
Q1 FY2024
As of May 31, 2023
|
Q4 FY2023
As of Feb 28, 2023
|
Q3 FY2023
As of Nov 30, 2022
|
Q2 FY2023
As of Aug 31, 2022
|
Q1 FY2023
As of May 31, 2022
|
Q4 FY2022
As of Feb 28, 2022
|
Q3 FY2022
As of Nov 30, 2021
|
Q2 FY2022
As of Aug 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash & cash equivalents | ||||||||||||||||||||
| Cash & cash equivalents | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Loans from related parties | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Common stock, $0.001 par value, 75,000,000 shares authorized;6,570,000 shares issued and outstanding | ||||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||||
| Common stock, $0.001 par value, 75,000,000 shares authorized; 6,570,000 shares issued and outstanding | ||||||||||||||||||||
| Additional Paid-In-Capital | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Total Stockholders' equity (deficit) | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity (Deficit) |
Loading...
